Evidence map›Paper›PMID 15956570›Full record

ArticleJournal of virology2005

Avian sarcoma and leukosis virus cytopathic effect in the absence of TVB death domain signaling.

Sara Klucking, Asha S Collins, John A T Young

Abstract read
In one paragraph

Article in Journal of virology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Oxidative Stress in Poultry: Lessons from the Viral Infections.Oxidative medicine and cellular longevity · 2018
    Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Sara KluckingEmory Vaccine Center, Emory University, Atlanta, Georgia 30322, USA.
Asha S Collins
John A T Young

Funding

MECHANISMS OF CELL KILLING INDUCED BY RETROVIRUSESR01CA062000 · NCI · UNIVERSITY OF WISCONSIN MADISON · PI YOUNG, JOHN A T · 1999 to 2003
$887k
ALSV-AENV/RECEPTOR INTERACTIONSR29CA062000 · NCI · J. DAVID GLADSTONE INSTITUTES · PI YOUNG, JOHN A T · 1994 to 1998
–
NCI NIH HHS CA62000NCI NIH HHS R01 CA062000
6 · The paper itself

Abstract

The cytopathic effect (CPE) seen with some subgroups of avian sarcoma and leukosis virus (ASLV) is associated with viral Env activation of the death-promoting activity of TVB (a tumor necrosis factor receptor-related receptor that is most closely related to mammalian TNF-related apoptosis-inducing ligand [TRAIL] receptors) and with viral superinfection leading to unintegrated viral DNA (UVD) accumulation, which is presumed to activate a cellular DNA damage response. In this study, we employed cells that express signaling-deficient ASLV receptors to demonstrate that an ASLV CPE can be uncoupled from the death-promoting functions of the TVB receptor. However, these cell-killing events were associated with much higher levels of viral superinfection and DNA accumulation than those seen when the virus used signaling-competent TVB receptors. These findings suggest that a putative cellular DNA damage response that is activated by UVD accumulation might act in concert with the death-signaling pathways activated by Env-TVB interactions to trigger cell death. Such a model is consistent with the well-established synergy that exists between TRAIL-signaling pathways and DNA damage responses which is currently being exploited in cancer therapy regimens.

Indexed as

Avian Leukosis VirusAvian Sarcoma VirusesBase SequenceCell AdhesionCell DeathCell LineCytopathogenic Effect, ViralDNA DamageDNA PrimersFlow CytometryGene Products, envHumansPolymerase Chain ReactionReceptors, VirusDNA PrimersGene Products, envReceptors, Virus

Identifiers

PMID15956570
PMCPMC1143719

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.